Form 4: Iteos Therapeutics Executive Yvonne McGrath Receives Stock Options and Restricted Stock Units

Yvonne McGrath, Chief Scientific Officer of Iteos Therapeutics, was granted stock options and restricted stock units (RSUs) on March 7, 2025, according to a recent SEC filing.

Summary

• Yvonne McGrath, Chief Scientific Officer of Iteos Therapeutics, received 91,000 stock options with an exercise price of $7.05 on March 7, 2025.
• These options vest over four years, with 25% vesting on March 7, 2026, and the remainder vesting in equal monthly installments over the following 36 months, contingent upon continued service.
• McGrath also received 15,300 restricted stock units (RSUs) on the same date.
• These RSUs vest over four years, with 25% vesting on March 7, 2026, and the remainder vesting annually over the subsequent three years, also contingent upon continued service.
• Following these transactions, McGrath directly owns 46,300 shares of Iteos Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no negative aspects presented in the document.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to attract, retain, and incentivize key executives. These grants align executive compensation with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants and RSU grants are standard practice in the biotech industry for executive compensation.
• Companies like Amgen, Gilead, and Regeneron use similar equity-based compensation packages to incentivize their executives.
• The vesting schedules described are also typical, with vesting periods of 3-4 years being common.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates